Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model

Li Zhong1, Ying Xu1, Rengong Zhuo2,3,4, Tingting Wang1, Kai Wang1, Ruizhi Huang1, Daxin Wang1, Yue Gao1, Yifei Zhu1, Xuan Sheng1, Kai Chen1, Na Wang1, Lin Zhu1, Dan Can1, Yuka Marten5, Mitsuru Shinohara5, Chia-Chen Liu5, Dan Du6, Hao Sun1, Lei Wen2, Huaxi Xu7, Guojun Bu5 & Xiao-Fen Chen1,4

Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial surface receptor genetically linked to the risk for Alzheimer’s disease (AD). A proteolytic product, soluble TREM2 (sTREM2), is abundant in the cerebrospinal fluid and its levels positively correlate with neuronal injury markers. To gain insights into the pathological roles of sTREM2, we studied sTREM2 in the brain of 5xFAD mice, a model of AD, by direct stereotaxic injection of recombinant sTREM2 protein or by adeno-associated virus (AAV)-mediated expression. We found that sTREM2 reduces amyloid plaque load and rescues functional deficits of spatial memory and long-term potentiation. Importantly, sTREM2 enhances microglial proliferation, migration, clustering in the vicinity of amyloid plaques and the uptake and degradation of Aβ. Depletion of microglia abolishes the neuroprotective effects of sTREM2. Our study demonstrates a protective role of sTREM2 against amyloid pathology and related toxicity and suggests that increasing sTREM2 can be explored for AD therapy.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most prominent cause of dementia in the elderly population. The histopathological hallmarks of AD include the parenchymal deposition of amyloid-β (Aβ) plaques, the formation of tau neurofibrillary tangles, and neuroinflammation. With the accumulation of these lesions in the brain, AD patients ultimately suffer from synaptic loss, neuronal death, and cognitive decline. Although the pathological events for AD are likely multifactorial, genetic, pathological, and functional studies suggest that the disequilibrium between Aβ production and clearance is a contributing and perhaps a driving event leading to AD. At present, enhancing the clearance of Aβ remains an attractive therapeutic or preventive strategy for AD. Microglia are effective phagocytes in the central nervous system (CNS) for the uptake and proteolytic clearance of both soluble and fibrillar forms of Aβ. Early studies have found that microglial cells are clustered around amyloid plaques in the brain of AD patients and AD mouse models. Recently, plaque-associated microglia have been shown to constitute a protective barrier that compacts amyloid fibrils and reduces their toxicity. The roles of microglia in AD have been further highlighted by recent genetic studies showing rare coding variants in several genes highly expressed in microglia as risk factors for late-onset AD. Trem2 is a type I transmembrane innate immune receptor predominantly expressed by microglia within the CNS. The ectodomain of TREM2 has been reported to bind anionic and zwitterionic lipids and apolipoproteins (including apoE, apolipoprotein B (apoB), and apoA) and lipoprotein particles. Recent studies have shown that TREM2 regulates microglial biosynthetic metabolism, proliferation, survival, cytokine release, and their accumulation around plaques. The impact of TREM2 on plaque accumulation was examined in Trem2-deficient AD mouse models, but the results were conflicting. Interestingly, a later study suggested disease progression-dependent effects of Trem2 deficiency ameliorate amyloid pathology early, but exacerbates it late in the disease process.

TREM2 undergoes regulated proteolytic cleavage by ADAM10 and ADAM17 at H157–S158 peptide bond, resulting in the liberation of soluble TREM2 (sTREM2). sTREM2 is abundantly detected in human cerebrospinal fluid (CSF) and its levels are elevated in the CSF of patients with sporadic AD. Interestingly, the levels of sTREM2 change dynamically during the progression of AD, peaking at the early symptomatic stages of the disease. Importantly, the CSF concentrations of sTREM2 correlate with neuronal injury markers, including the CSF levels of total tau and phospho-tau; thus, they may serve as an immunomodulatory biomarker for neurodegeneration. Remarkably, sTREM2 was found to co-localize with neurons and plaques in vivo, with functions remaining to be determined. We have recently reported that sTREM2 exerts functional roles in microglia by promoting inflammatory responses and shielding them from apoptosis. However, whether sTREM2 also has protective effects against amyloid pathology and the related synaptic toxicity remains to be defined. In this study, we explored the effects of sTREM2 on pathological phenotypes in 5xFAD mouse model by direct stereotaxic injection of recombinant sTREM2 protein or by an adenovirus-associated virus (AAV)-mediated expression strategy. We found that sTREM2 reduces amyloid-β (Aβ) pathology and improves cognitive and synaptic functions by modulating microglial activity in 5xFAD mouse model, thus providing a rationale that sTREM2 can be explored for AD therapy.

**Results**

**sTREM2 reduces plaque load and the associated toxicity.** We had previously developed a mammalian expression and purification system for recombinant sTREM2 protein (Supplementary Fig. 1a). To assess the impact of sTREM2 on AD-related pathology, we injected a recombinant sTREM2 protein into the right hippocampus of 5xFAD mice, with phosphate-buffered saline (PBS) injected into the left hippocampus as a vehicle control (Fig. 1a). Twenty-four hours after stereotaxic injection of sTREM2, immunofluorescence staining with human Trem2 antibody showed a sTREM2 distribution pattern that is diffused but limited to the right hippocampus (Supplementary Fig. 1b). However, the sTREM2 signal decayed thereafter and was barely detectable on day 3 and 7 after injection. Seven days after delivery to the hippocampus of 5xFAD mice, sTREM2 dramatically reduced the amyloid plaque load in the ipsilateral hippocampus (Fig. 1b, c). Of note, the number of large plaques (>40 μm in diameter) was markedly reduced by sTREM2 (P < 0.0001, paired Student's t test) (Fig. 1d).

In addition to the amount of Aβ accumulation, the degree of plaque compaction plays a crucial role in determining the neurotoxicity of the plaque. It has been suggested that microglia clustered around the amyloid plaque constitute a barrier which impacts plaque composition and toxicity. To gain insight into the effects of sTREM2 on microglial barrier function, we quantified the number of microglia in the vicinity of an amyloid plaque and found a significant increase upon sTREM2 administration (Fig. 1e, f). Consistent with its protective effects on plaque deposition, sTREM2 significantly reduced the total area of dystrophic neurites, as detected by immunostaining with an antibody against Lamp1 (Figs. 1g, h). However, no significant differences were observed between vehicle and sTREM2 treatment when calculating the amount of dystrophic neurites per plaque (Fig. 1i). Thus, distinct from the full-length TREM2, sTREM2 is unlikely involved in compacting amyloid fibrils to reduce their toxicity. Collectively, these data reveal that sTREM2 protein reduces amyloid plaque deposition and enhances the clustering of microglia in the vicinity of the plaque, thereby reducing plaque load and the plaque-associated neurotoxicity.

**sTREM2 promotes microglial proliferation and migration.** Proliferation and activation of microglia around the sites of amyloid plaque deposition is a prominent feature of AD. The ionized calcium-binding adapter molecule 1 (Iba1) is widely employed as an immunohistochemical marker for both ramified and activated microglia, and its expression is increased upon microglial activation. We found that the expression of Iba1 in the hippocampus of 5xFAD mice was significantly increased at the protein level, and a trend toward increased mRNA level upon sTREM2 administration (Fig. 2a–c). However, no significant differences were detected for the astrocytic marker GFAP. Staining of brain sections further revealed that sTREM2 administration led to a significantly higher number of proliferating microglia (Iba1+/Ki67+) and the total number of microglia (Iba1+) in the hippocampus (Fig. 2d–f). Interestingly, the increased Iba1 staining induced by sTREM2 on day 1 was sustained throughout day 7, even though sTREM2 was barely detectable on day 3 and 7 after injection (Supplementary Fig. 1b). In addition to Iba1, the expression levels of
pro-inflammatory cytokines, including IL-1β and TNF, were significantly increased in the presence of sTREM2 (Supplementary Fig. 2a), consistent with our previous report that sTREM2 promotes microglial activation. Importantly, both the pro-inflammatory cytokine IL-1β and the immune-activating molecule lipopolysaccharide enhanced the production of sTREM2 in primary microglia, as measured by enzyme-linked immunosorbent assay (ELISA); while the anti-inflammatory cytokine IL-10 had a minimal effect (Supplementary Fig. 2b). Therefore, sTREM2 and the pro-inflammatory cytokines appear to form a positive feedback loop, resulting in sustained microglial activation.

Since sTREM2 increases the number of plaque-associated microglia, we further tested a hypothesis that sTREM2 might act as a chemoattractant to promote microglial migration. Primary microglia isolated from wild-type (WT) mice were subjected to the transwell migration assay in the presence or absence of sTREM2. Interestingly, treatment with native but not heat-inactivated sTREM2 led to increased migration of microglia, as compared with the vehicle control (Fig. 2g, h). Our data hence suggest that sTREM2 not only enhances microgliosis in 5×FAD mice, but also acts as a chemoattractant for microglia.
sTREM2 promotes microglial phagocytosis and clearance of Aβ. Microglia clustering in the vicinity of plaques is interpreted as an attempt to clear the pathological deposits of Aβ through phagocytosis and degradation. Indeed, quantitative assessment of the area of colocalization of Aβ with CD68, a phagocytic marker for microglia in the brain, revealed a significant increase in sTREM2-injected 5×FAD mice (Fig. 3a, b), suggesting that sTREM2 likely promotes phagocytic Aβ uptake by microglia. To further test this in vivo, we administered intraperitoneally methoxy-X04 3 h prior to microglial isolation and analyzed the proportion of methoxy-X04-positive microglial cells by flow cytometry. Comparing PBS-injected WT mice and 5×FAD mice treated with native or heat-inactivated sTREM2 revealed a significant increase in the number of CD11b⁺CD45low resident microglia in sTREM2-administered 5×FAD mice, while no significant change was observed for the number of CD11b⁺CD45high peripheral macrophage (Fig. 3c, d). Therefore, the increased number of Iba1-positive cells upon sTREM2 treatment is likely contributed by resident microglia rather than infiltrating macrophages. A significant increase in the proportion of methoxy-X04-positive microglial cells was observed for 5×FAD mice injected with native sTREM2 (Fig. 3e, f), further demonstrating that sTREM2 enhances microglial phagocytosis of Aβ in vivo.

We further examined the effects of sTREM2 on Aβ uptake and/or degradation in cultured microglial cells. Primary postnatal microglia isolated from WT mice were incubated with fluorescently FAM-labeled Aβ42 (FAM-Aβ42). We found an increase in FAM-Aβ42 uptake upon sTREM2 stimulation (Fig. 3g, h). However, the effect was diminished in the presence of a phagocytosis inhibitor cytochalasin D. To further investigate the role of sTREM2 in microglial Aβ endocytic trafficking, we incubated microglial cells with Aβ, together with vehicle control or sTREM2 in the presence or absence of lysosomal enzyme inhibitors ( Pepstatin A, Leupeptin, and E-64d) or chloroquine. Cell-associated Aβ levels were significantly increased by sTREM2 in the presence of lysosomal inhibitors (Fig. 3i and Supplementary Fig. 3a). When lysosomal degradation of Aβ was calculated by subtracting the cell-associated Aβ in the absence of inhibitors from that in the presence of inhibitors, we found that sTREM2 significantly enhanced Aβ lysosomal degradation, as compared with vehicle control (Fig. 3j and Supplementary Fig. 3b).

Since the steady-state levels of brain Aβ represent a dynamic equilibrium between its rate of clearance and production from the amyloid precursor protein (APP), we further explored the molecular mechanism by which sTREM2 reduces Aβ levels. We performed a series of experiments to evaluate whether sTREM2 induces changes in the levels of APP, its cleavage products, or Aβ-degrading enzymes in sTREM2-injected 5×FAD mice. No significant changes in the levels of full-length APP, α-CTF, or β-CTF were detected upon sTREM2 injection in 5×FAD mice (Supplementary Fig. 3c, d). Quantitative real-time polymerase chain reaction (PCR) of the transcript levels of Aβ-degrading enzymes, including insulin-degrading enzyme (IDE), neprilysin (NEP), endothelin-converting enzyme 1 (ECE1), matrix metalloproteinase 2 (MMP2), and matrix metalloproteinase 9 (MMP9), did not detect any significant alterations in response to sTREM2 treatment (Supplementary Fig. 3e). Taken together, we provide both in vivo and in vitro evidence that sTREM2 promotes microglial phagocytosis and clearance of Aβ, which may account for sTREM2-mediated reduction of Aβ deposition in the brain of 5×FAD mice.

Microglia are essential for the protective effects of sTREM2. Both our current and previous studies pinpoint a critical role of sTREM2 in modulating microglial function. To determine whether microglia mediate the protective effects of sTREM2 on amyloid pathology, we employed the CSF1R inhibitor PLX3397 to deplete microglia from 5×FAD mice. Following 14 days of PLX3397 treatment, microglial number as assessed by Iba1 staining was substantially reduced, with efficiency comparable with the previous work in 5×FAD mice (Supplementary Fig. 4a, b). Consistent with previous reports that microglial elimination in 5×FAD mice prevents neuronal loss, increased levels of synaptic markers (including NR2A, NR1, GluR1, and vGluT1) were observed in PLX3397 administered to 5×FAD mice (Supplementary Fig. 4c, d). However, no significant changes in the levels of full-length APP, α-CTF, or β-CTF were detected upon PLX3397 treatment. To determine if microglia are responsible for sTREM2-mediated plaque reduction, we depleted microglia with 14 days of PLX3397 treatment, followed by administering sTREM2 to the hippocampus of 5×FAD mice (Fig. 4a). In contrast to the control without PLX3397 treatment, the plaque load was no longer reduced by sTREM2 in 5×FAD mice treated with PLX3397, suggesting an indispensable role of microglia in sTREM2-mediated plaque reduction (Fig. 4b, c).

Next, we studied the impact of sTREM2 administration on hippocampal synaptic plasticity by inducing long-term potentiation (LTP) in the Schaffer collateral (SC) pathway with high-frequency stimulation. Intriguingly, the LTP impairment of 5×FAD mice was ameliorated when acute hippocampal slices obtained from 5×FAD mice were pre-incubated with sTREM2 protein, as compared with the vehicle control (Fig. 4d, f). More interestingly, such effects were diminished in microglia-depleted 5×FAD mice (Fig. 4e, f), suggesting that microglia mediate the protective functions of sTREM2 in synaptic plasticity. In contrast to the 5×FAD mice, sTREM2 had
minimal effects on the LTP in either microglia-intact or microglia-eliminated WT mice (Supplementary Fig. 4e–g). To better understand synaptic alterations upon sTREM2 administration, we examined the levels of various proteins involved in synaptic plasticity and function. The levels of postsynaptic glutamate (AMPAR) receptor subunits (GluR1 and GluR2) and the presynaptic vesicular glutamate transporter 1 (vGluT1) were significantly increased upon sTREM2 treatment in the hippocampus (Fig. 4g, h). However, sTREM2 could no longer increase the levels of these proteins in the absence of microglia (Fig. 4i, j).

Recently, sTREM2 was found to co-localize with neurons in vivo. To further investigate whether neurons directly respond to sTREM2, primary neuronal cultures at DIV 12–14 were incubated with sTREM2 and subjected to whole-cell patch-clamp experiments to record miniature excitatory postsynaptic currents.
(mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs). The amplitude and frequency of both mEPSCs and mIPSCs did not significantly differ between Fc- and sTREM-Fc-treated groups (Supplementary Fig. 4h–k). Furthermore, sTREM2 did not affect the abundance of synaptic proteins in the primary neuronal cultures (Supplementary Fig. 4l, m), suggesting that sTREM2 does not directly modulate synaptic plasticity and function. Taken together, these data indicate that microglia play an indispensable role in mediating the protective effects of sTREM2 on amyloid plaque pathology and synaptic plasticity.

Validation with physiologically produced sTREM2. At the time we started this project, the precise TREM2 cleavage site to
generate sTREM2 was unknown. More recently, it was reported that TREM2 undergoes regulated shedding at the H157–S158 peptide bond, resulting in the liberation of soluble TREM2 ending at position 157 (sTREM2-157)33–37. Hence, we went on to test whether the physiological form of sTREM2-157 protein recapitulates the functions that we defined for the sTREM2-171 mimics (Fig. 5a). Consistent with our previous findings 43, the sTREM2-157 protein was as efficient as the sTREM-171 in both suppressing microglial apoptosis and stimulating the production of inflammatory cytokines (Fig. 5b, c). Furthermore, the native sTREM2-157 protein but not its heat-inactivated form significantly stimulated the migration of microglial cells, consistent with the role of sTREM2-171 protein as a chemoattractant for microglia (Fig. 5d, e). Importantly, the sTREM2-157 protein largely and significantly decreased the deposition of amyloid plaques and promoted the clustering of microglia in the vicinity of plaques (Fig. 5f–i). However, sTREM2 lost these protective functions upon heat inactivation, indicating that the native protein structure is required for sTREM2 function (Supplementary Fig. S5). We therefore conclude that the physiological form of sTREM2 protein functions as efficiently as the sTREM2-171 in modulating microglial responsiveness and decreasing plaque deposition in 5×FAD mice.

**Long-term expression of sTREM2 reduces Aβ pathology.** To validate the findings from recombinant sTREM2 protein and to further assess the long-term impact of sTREM2 on AD-related pathology, we expressed sTREM2 in the brain of 5×FAD mice using AAV-mediated expression approach. Viruses carrying cDNAs encoding EGFP alone as a control or EGFP-2A-sTREM2-3×FLAG (spanning N-terminal amino acids 1–171 of TREM2) were injected into the cerebral ventricles of P0 neonatal 5×FAD mice. Seven months after viral injection, we found similar distribution patterns of EGFP expression in control and sTREM2-injected brains, including the cortex and hippocampus (Supplementary Fig. 6a). By analyzing potential colocalization of sTREM2 with cell-type-specific markers for astrocytes, microglia, and neurons, we found that the sTREM2 signal was colocalized primarily with NeuN-positive neurons, but not with GFAP-positive astrocytes or Iba1-positive microglia (Supplementary Fig. 6b). The absence of AAV infection to microglial cells is consistent with the previous observation that microglia are refractory to AAV 49. Transduction of primary neurons with the sTREM2 expression construct showed that sTREM2 was efficiently secreted into the media (Supplementary Fig. 6c, d). Thus, sTREM2 possesses the tendency to contact any cell type in the brain, including microglia, after releasing into the extracellular space. The mRNA levels of sTREM2 in the cerebral cortex and hippocampus were significantly increased in 5×FAD mice, as compared with the EGFP control (Fig. 6a). This increase was further confirmed at the protein level using ELISA to measure the levels of sTREM2 in the TBS-soluble fractions (Fig. 6b).

We next evaluated the effects of sTREM2 expression on Aβ levels and plaque deposition. We found that sTREM2 significantly decreased the total plaque burden in both the hippocampus and the cortex of sTREM2-expressing 5×FAD mice relative to controls (Fig. 6c, d). Congo red-positive dense core compact plaques were also reduced in the presence of AAV-mediated sTREM2 expression (Supplementary Fig. 7a, b). To further analyze how sTREM2 affects the dynamic pools of Aβ, we examined Aβ levels in sequentially extracted triss-buffered saline (TBS)-soluble, detergent-soluble (TBSX), and detergent-insoluble (guanidine-HCl, GDN) fractions from cortical and hippocampal mouse brain tissues by ELISA 50. The majority of Aβ in these mice at 7 months of age was fractioned in the detergent-insoluble fractions, reflecting its deposition in the amyloid plaque (Supplementary Fig. 7c, d). Consistent with decreased Aβ deposition, the concentrations of insoluble Aβ42 in the guanidine fractions were significantly lower in the cortex and hippocampus of sTREM2-expressing 5×FAD mice than the control. There were no changes in Aβ levels in TBS-soluble and TBSX-soluble fractions. Furthermore, AAV-mediated sTREM2 expression had no significant effects on the levels of APP, its cleavage products, or Aβ-degrading enzymes, consistent with the effects that we observed using a recombinant sTREM2 protein (Supplementary Fig. 7e–g). In the presence of sTREM2 expression, the number of plaque-associated microglia was significantly increased in both the hippocampus and the cortex of 5×FAD mice (Fig. 6e, f). Taken together, AAV-mediated sTREM2 expression ameliorates plaque deposition and enhances microglial enrichment in the vicinity of an amyloid plaque.

**AAV-mediated sTREM2 expression rescues behavioral deficits.** We further evaluated if the beneficial effects of sTREM2 expression in reducing amyloid plaque deposition are associated with improved synaptic plasticity and cognitive function of 5×FAD mice. To analyze the potential impacts of sTREM2 expression on AD-related behavioral deficits, the spatial learning and memory function of experimental mice were evaluated by the Morris water maze 6 months after viral injection. Similar to the 5×FAD mice, the mRNA and protein levels of sTREM2 in the cerebral cortex and the hippocampus detected 7 months after AAV injection were significantly increased in WT mice (Fig. 7a, b). The 5×FAD mice were less efficient at finding the hidden platform than WT mice, indicating a deficit in spatial learning ability at 6 months of age (Fig. 7c). Importantly, sTREM2 expression rescued this spatial learning deficit, as evidenced by a reduced latency to reach the platform over the 7 days of training.
Fig. 4 Depletion of microglia attenuates the protective effects of sTREM2 on Aβ pathology and synaptic plasticity. a Scheme for PLX3397 administration and sTREM2 injection in 5×FAD mice. The 5×FAD mice were fed with either PLX3397 or control chow for 14 days and then injected with either sTREM2 protein or vehicle control. After continued feeding with PLX3397 or control chow for 7 days, coronal sections were stained with DAPI (blue) for nuclei, MOAB-2 (green) for Aβ, and Iba1 (red) for microglia. Representative images of the hippocampus region are shown. Original magnification ×20; scale bar, 100 μm. c Quantitation of amyloid plaque deposition in b (n = 5 mice, 18 fields of ctrl and 22 fields of PLX3397 for analysis, paired Student’s t test).

d, e Brain slices from control chow (d) or PLX3397-fed (e) 5×FAD mice were incubated with 50 nM recombinant sTREM2 protein for 1 h at room temperature, and transferred to the chamber for LTP recording. Time course of fEPSP measures were recorded in the hippocampal CA1 region before and after 100-Hz stimulation in the Schaffer collateral region. Normalized fEPSP slopes were plotted every 1 min for each group.

f The averaged fEPSPs recorded 50–60 min after induction of LTP (n = 10 slices for Ctrl, n = 6 slices for PLX3397, four mice per group, unpaired Student’s t test).

g, h Synaptic proteins from the hippocampi were analyzed by Western blotting 7 days after vehicle or sTREM2 protein injection to the 5×FAD mice fed with control chow. h Quantitation of Western blots in g (n = 8 mice per group, paired Student’s t test).

i, j Synaptic proteins from the hippocampi were analyzed by Western blotting 7 days after vehicle or sTREM2 protein injection to the 5×FAD mice fed with PLX3397. j Quantitation of Western blots in i (n = 6 mice per group, paired Student’s t test). All data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
During the probe trials conducted 24 h after the last training, the 5xFAD mice receiving sTREM2 viruses spent significantly more time in the target quadrant than those receiving control viruses (Fig. 7d). However, expression of sTREM2 did not affect the spatial memory of WT mice in either the hidden platform tests or probe trials (Fig. 7c, d). As controls, swim speeds were comparable in all groups of animals, thus excluding impairments in motor function (Fig. 7e). These data indicate that sTREM2 expression could rescue the spatial memory impairments in 5xFAD mice.
We next examined whether sTREM2-mediated memory improvement in 5xFAD mice was reflected at the synaptic level. We thus studied the hippocampal synaptic plasticity in the same set of animals as used for the behavioral study. Consistent with previous studies, the 5xFAD mice showed significantly impaired LTP as compared with WT mice (Fig. 7f, g)\(^{51}\). Importantly, the magnitude of LTP measured during the last 10 min post induction (51–60 min) was significantly higher in sTREM2-expressing 5xFAD mice relative to control mice (Fig. 7g). However, sTREM2 expression had a minimal effect on hippocampal LTP in WT mice. Thus, AAV-mediated expression of sTREM2 largely and specifically ameliorated LTP deficits in 5xFAD mice. Taken together, our study reveals that sTREM2 expression could rescue or ameliorate key Aβ/amyloid-induced AD phenotypes, including defective synaptic plasticity and impaired spatial memory.

**Discussion**

Although it has been widely acknowledged that the CSF levels of sTREM2 are elevated in AD, it remains unknown how sTREM2 impacts the amyloid pathology and microglial behaviors in the disease context. In the present study, we demonstrated for the first time that sTREM2 is capable of reducing amyloid deposition, ameliorating synaptic impairments and memory deficits in the 5xFAD mouse model. Intriguingly, these protective effects of sTREM2 were attenuated by the depletion of microglia, suggesting a crucial role for microglia in mediating sTREM2 function. Indeed, sTREM2 enhances a variety of microglial activities known to control amyloid pathology, including microgliosis, migration, clustering in the vicinity of an amyloid plaque, as well as uptake and degradation of Aβ. As the accumulation and deposition of Aβ in the brain likely drives the pathogenic cascades of AD\(^{4, 52, 53}\), our study provides a critical link between Aβ pathology and the emerging role of microglia-mediated innate immune response in the pathogenesis of AD\(^{54, 55}\).

Recent studies have begun to unravel the specific roles of TREM2 in modulating microglial functions. For example, the deficiency of TREM2 has been shown to decrease the number of plaque-associated microglia, reduce plaque compaction, and axonal dystrophy\(^{11, 56}\). The TREM2 signaling pathways also play key roles in regulating Aβ uptake by microglial cells; loss of TREM2 results in reduced phagocytosis, while increased TREM2 gene dosage enhances phagocytic activity\(^{11, 57}\). Intriguingly, the above-mentioned functions as well as the effects on microglial proliferation and migration by full-length TREM2 are well recapitulated by sTREM2. Since the soluble version of another TREM family member TREM1 was found to negatively modulate TREM1 signaling, initially, sTREM2 was postulated to similarly compete with its membrane-bound form to block TREM2 function. Nevertheless, our data suggest that sTREM2 possesses important biological and pathological roles other than acting as a decoy receptor opposing full-length TREM2 signaling.

Although many functional aspects of sTREM2 resemble those of membrane-bound TREM2, they are not identical. The biological actions of sTREM2 do not require the presence of full-length TREM2 or its intracellular adapter DAP12\(^{43}\). Moreover, the full-length TREM2 has been found to promote the formation of a neuroprotective microglia barrier that regulates amyloid compaction and insulation, thereby reducing axonal dystrophy around amyloid deposits. Despite a clear reduction of plaque deposition and the total area of dystrophic neurites by sTREM2, it does not significantly impact the amount of dystrophic neurites per plaque and thus unlikely contributes to compacting amyloid fibrils (Fig. 1). Recently, comprehensive single-cell RNA analysis of CNS immune cells in neurodegenerative conditions has discovered an essential role of TREM2 in the activation of disease-associated microglia\(^{58, 59}\). In future studies, it will be informative to perform transcriptomics analysis at the single-cell level to examine how sTREM2 modulates microglial gene expression in the diseased brain.

A recent study reported that sTREM2 released from cell membranes latches onto amyloid plaque and nearby neurons\(^{42}\), indicating a direct physical interaction between sTREM2 and amyloid plaques/neurons. In fact, we have found that an oligomeric Aβ\(^{42}\) specifically binds to sTREM2 with a high affinity\(^{26, 27}\). In addition, sTREM2 also binds to apoE, another major component of amyloid plaques\(^{23–25}\). Hence, sTREM2 is likely present in amyloid plaques and acts as a chemoattractant for microglial recruitment to the vicinity of a plaque. Although sTREM2 has been reported to co-localize with neurons in vivo, incubation of primary neuronal cultures with sTREM2 in the absence of microglia had minimal effects on the abundance of the synaptic proteins or the amplitude and frequency of both mEPSCs and mIPSCs (Supplementary Fig. 4). However, sTREM2 significantly increased the levels of several synaptic proteins and rescued the impaired LTP when administered to the brains of 5xFAD mice (Fig. 4). Intriguingly, the protective effects of sTREM2 on amyloid load and synaptic function were attenuated by the presence of a selective CSF1R kinase inhibitor, PLX3397, which nearly eliminates microglia from the 5xFAD mice (Fig. 4). Hence, our data support that microglia are the main effector cells that mediate the protective functions of sTREM2 in the context of AD. However, the microglial surface receptor(s) for sTREM2 remain unknown. Considering the fact that TREM2 is a highly promiscuous receptor engaging a wide array of ligands, the receptor(s) for sTREM2 might also be highly redundant and needs to be systematically investigated in future studies.
Although the precise mechanism mediating the ability of sTREM2 to attenuate AD pathology remains to be determined, we speculate that significantly reduced levels of Aβ and plaque load upon sTREM2 treatment may contribute to the rescue of synaptic failure and memory deficits in the case of long-term sTREM2 exposure (AAV-mediated sTREM2 expression). However, it is unlikely that the decreased amyloid plaque is responsible for improved LTP in brain slices that were treated with sTREM2 for only 1 h. There are several previous studies that have linked microglia-related functions to synaptic plasticity. For example, Parkhurst et al. showed that microglia promote learning-induced formation of glutamatergic synapses and that this effect is mediated by microglia-released brain-derived neurotrophic factor. In addition, it has been demonstrated that TNF and IL-1β released by microglial cells enhance synaptic transmission and neuronal activity. Our current study has clearly shown that sTREM2 exerts its effects in a microglia-dependent manner. Thus, it is possible that sTREM2 positively
modulates synaptic plasticity by promoting neurotrophic functions of microglia. Taken together, our data suggest that sTREM2 might exert its protective functions in AD by both amyloid-dependent and amyloid-independent pathways.

In conclusion, our data provide strong evidence that sTREM2 elevation of sTREM2 represents a protective response against disease-related and amyloid-independent pathways. Taken together, our data suggest that sTREM2 might exert its protective functions in AD by both amyloid-dependent and amyloid-independent pathways.

Methods
Mice. All animal experiments were approved by the Animal Ethics Committee of the Xiamen University and were conducted in compliance with all relevant ethical regulations for animal testing and research. Sample sizes were adequately powered to observe the effects on the basis of past experience of animal studies. Mice...
were randomly selected for further biological analysis, and the investigators were blinded to group allocation during the experiments or outcome assessments. For AAV injection, postnatal P0 mice within each genotype (WT or sTREM2 mice) were injected with control AAV or AAV-sTREM2, and both males and females were used in this study. The behavioral tests were performed at 6 months of age for LTP and biochemical analysis, samples were harvested from AAV-injected Wistar rats at 5 months.

For sTREM2 protein injection, 5xFAD mice at 7 months of age were injected with control PBS or heat-inactivated sTREM2 or native sTREM2 protein into the left and right hippocampus, respectively. Seven days after injection, mice were anesthetized and perfused with ice-cold PBS. Samples were harvested for biochemical or histological analysis. Both males and females were used in this study.

To pharmacologically ablate microglia in the brain, 6-month-old (for LTP) or 7-month-old (for amyloid plaque) 5xFAD mice were fed with PLX3397 (Selleck, S8718, 290 mg/kg formulated in standard chow)64,65. Age-matched control groups were fed with the same standard chow without but with PLX3397.

**Injection of AAV.** The AAV2/8 viruses expressing human EGFP-2A-sTREM2-3xFLAG (1–171aa) (AAV-sTREM2) or EGFP (control AAV) under the control of the CAG promoter were generated by the Ohio Technology (Shanghai). Neonatal mice were cryoanesthetized on ice for 3 min before AAV injection. Following cessation of movement, viruses were injected into the lateral ventricles of both cerebral hemispheres with 7.5 × 10^5 total viral particles per side using a 0.5-μl syringe (Hamilton, 7642-01) with a 30-G needle (Hamilton, 7805-07). After both injections were completed, pups were placed on a warming pad until they regained normal color and resumed movement. All injected pups were then returned to their mothers for care and further recovery.

**Tissue preparation.** Mice were anesthetized and transcardially perfused with 50 ml of ice-cold 1× PBS. Brains were removed and dissected at the midline. For biochemical analysis, the cortex and hippocampus were dissociated and immediately snap-frozen in liquid nitrogen and stored at −80 °C for extraction of protein and RNA. For immunohistochemistry analysis, brains were immersed in 4% paraformaldehyde (PFA, Sigma-Aldrich, P1668) overnight at 4 °C, followed by transferring to 30% sucrose at 4 °C for 48 h, before being embedded for cryostat sectioning.

**Western blotting.** Samples were homogenized and incubated in RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific, 89900), supplemented with Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78440). Protein content was measured using the Bio-Rad Protein Assay (Bio-Rad). Protein samples were separated on SDS-PAGE gels and transferred to PVDF membranes. Membranes were blocked in 5% non-fat milk and then incubated with primary antibodies for 2 h at room temperature. After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibody and imaged using the Bio-Rad ChemiDoc Touch Imaging System.

**RNA isolation and real-time quantitative PCR analysis.** Total RNA was isolated from the cortex or the hippocampus using TRIzol reagent (Thermo Fisher Scientific, 15596018). One microgram of RNA was reverse-transcribed into the first-strand cDNA using a DNA Synthesis SuperMix (TransGen Biotech, China, AT314-02) according to the manufacturer’s instructions. Real-time quantitative PCR was performed using the FastReal Fast SYBR Green Master Mix (TransGen Biotech, China, AT314-02) according to the manufacturer’s instructions. Equal amounts of total proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to PVDF membranes. Membranes were blocked by a primary antibody and detected with horseradish peroxidase-conjugated secondary antibody. Proteins were visualized using ECL (enhanced chemiluminescence detection reagent, Millipore, WBKLS0500). Primers used for the real-time PCR were listed in Table S2. For detection of immunoreactive bands, the images were captured and quantified using ImageJ software. The following antibodies were used: anti-α-tubulin (Wako, 016-20001, 1:5000), anti-GAPDH (Cell Signaling Technology, 5174S, 1:10000), anti-Glut1 (Millipore, MAB2623, 1:10000), anti-Glut2 (Millipore, AB1768-L, 1:10000), anti-PSD95 (Cell Signaling Technology, 4305S, 1:2000), anti-VASP (Millipore, MAB5502, 1:2000), anti-Synaptophysin (Sigma-Aldrich, S5768, 1:20000), anti-APP C-terminal (36969, in-house, 1:20000), anti-TREM2 (R&D Systems, AF1828, 1:5000), and anti-a-Tubulin (Millipore, MAB205, 1:5000).

Microglial migration in transwell assays. Mixed glial cultures were isolated from WT mice at postnatal day 1–2 and were plated onto poly-l-lysine-coated flasks and grown in DMEM supplemented with 10% fetal bovine serum (FBS) (Gibco). After 3 days, the medium was changed to that which contained 25 ng/ml granulocyte-macrophage CSF (GM-CSF) and 10% FBS. Primary microglial cells were harvested by shaking after 10–12 days in culture and once every 3 days thereafter (up to four harvests). Microglial migration was performed in inserts with a 8-μm pore (Costar, 3422). Primary microglial cells (10^5) suspended in 100 μl of serum-free DMEM were added to the upper chamber of the inserts with 600 μl of serum-free DMEM in the bottom chamber. After 1-h incubation at 37 °C and 5% CO₂, the bottom medium was replaced with DMEM containing PBS (vehicle), 100 nM native sTREM2, or heat-inactivated sTREM2 and the culture continued for 24 h. For analysis of the migrated cell number, cells remaining on the upper surface of the membrane were removed by scraping with a cotton swab and the inserts were washed three times with PBS. Cells were then fixed with 4% PFA for 20 min, followed by staining with hematoxylin and eosin. The total number of counts was calculated and the migrated cells were quantified for the microglial migration was normalized to the total number of cells.

**ELISA analyses.** For Aβ ELISA, the cortex or the hippocampus was sequentially extracted with TBS, TBSX, and guanidine-HCl (GDN)66. The levels of Aβ40 or Aβ42 were measured using sandwich ELISA techniques with monoclonal antibody (rabbit Ab40 (human Aβ40–42, 20 μg/ml, in-house) and rabbit Ab42 (human Aβ40–40, 20 μg/ml, in-house) for capture and horseradish peroxidase (HRP)-conjugated mAb Ab5 (human Aβ1–16, 1 μg/ml, in-house) for detection64. The ELISA was developed using ELISA TMB (Sigma-Aldrich, T8665). Synthetic human Aβ40 (AnaSpec, AS-24266) or Aβ42 peptide (AnaSpec, AS-20276) was used to generate the standard curves for each assay. In-house mouse sTREM2 ELISA assay was established in-house. A 96-well plate was coated with a TREM2 antibody (R&D Systems, MAB1729, 100 μg/ml) in coating buffer (0.05 M Carbonate buffer, pH 9.6) overnight at 4 °C. The plate was then blocked in blocking buffer (1% Block Ace in PBS) for 4 h at room temperature, RT, subsequent washes, and antibody incubation. A secondary antibody (The Binding Site, 1:10000), anti-Mouse IgG-HRP (Jackson, 605-2000-01) was added (1 μg/ml), followed by a 30-min incubation. The ELISA was developed using ELISA TMB (Sigma-Aldrich, T8665). After the washing steps, the plates were incubated with Tetramethyl Poly-HRP-40 Conjugate (Fischer, 65R-S104PHRP, 1:10000) in 1 h for the detection of Aβ. After five additional washing steps, the plates were developed by adding the TMB substrate (Sigma-Aldrich, T5695) and read at 620 nm on a Varicons Flash Multimode Reader (Thermo Fisher Scientific).

**Immunochemistry and microscopy.** Mouse coronal sections were cut (12-μm thick) with a cryostat and mounted on poly-l-lysine precoated glass slides, air-dried overnight at 37 °C. The slides were then stored at −80 °C for subsequent imaging. Sections were washed in 1× PBS for 15 min and incubated with blocking buffer (PBS with 5% normal donkey serum and 0.2% Triton X-100) for 1 h at RT, followed by incubation with primary antibodies for 4 h at 4 °C and the Alexa-fluorophore-conjugated secondary antibody (The Binding Site, 1:10000). After the washing steps, the slides were incubated with Streptavidin Poly-HRP-40 Conjugate (Fischer, 65R-S104PHRP, 1:10000) in 1 h for the detection of Aβ. After five additional washing steps, the slides were developed by adding the TMB substrate (Sigma-Aldrich, T5695) and read at 620 nm on a Varicons Flash Multimode Reader (Thermo Fisher Scientific).

**Brain stereotaxic injection.** The 5xFAD mice at 7 months of age were anesthetized and placed in a stereotaxic frame, a skin incision was made, and holes were drilled at x (±2.0 mm from bregma) and y (±2.0 mm from bregma) and z (−2.0 mm from bregma) and z (−2.0 mm from bregma). A total of 6 μl of sTREM2 protein in 2.0 μl of PBS, or heat-inactivated sTREM2 in 2.0 μl of PBS, or 2.0 μl of PBS alone was delivered at 0.20 μl/min at z-depths of 2.0 mm to the right and left hemispheres, respectively. The syringe was left in place for 10 min after injection before being slowly removed. After injection, mice were anesthetized and perfused with ice-cold PBS. For biochemical analysis, hippocampi were collected from the left or right brain and dissected out, snap-frozen in liquid nitrogen and stored at −80 °C for further analysis.
Aphagocytosis assays. For the in vitro assay, primary microglial cells were seeded into 12-well culture plates at a density of 2 x 10^4 cells per well and were cultured for 24 h after GM-CSF withdrawal. Cells were treated with 160 nM sTREM2 protein in serum-free DMEM for 12 h, followed by treatment with a phagocytosis inhibitor cytochalasin D (Calbiochem, 250253, 10 µM) for 30 min and incubation with 300 nM FAM-Aβ42 oligomer for an additional 3 h. Cells were then washed and combined with cPLA2 for detection of FAM fluorescence-activated cell sorting (FACS). The in vivo phagocytosis assay was performed, as described previously with slight modifications. The 7-month-old 5xFAD mice were injected with sTREM2 as described above. After 7 days, mice were injected intraperitoneally with methoxy-X04 (Toris, 4920) at 10 mg/kg in 10% DMSO/0.9% PBS (m: v = 1: 12) for 3 h. Anesthetized mice were perfused with cold PBS and the hippocampi were isolated and chopped into pieces and digested in DMEM/F12 containing 1 mg/mL Papain (Sigma, P4762), 1.2 U/mL Dispase II (Sigma, D4693), 20 U/mL DNase I (Sigma, D5025), and 100 U/mL Collagenase IV (ThermoFisher, 17104019) at 37 °C for 30 min. The homogenization was achieved by pipetting gently up and down. The homogenates were washed and filtered through a 70-µm cell strainer. Hippocampal cells were centrifuged at 500 g for 5 min at 4 °C and resuspended in PBS. Cells were incubated with the Fc receptor blocking antibody CD16/CD32 (BD Biosciences, 553411, 1:100) for 10 min at 4 °C to prevent unspecific binding. Cells were washed once and then resuspended in 200 µL 1X 1011 APC (eBioscience, 01-800-100) and CSMT- FITC (eBioscience, 11-0451-85, 1:100) and incubated for 1 h at 4 °C. Cells were washed again and resuspended in 2% FBS/PBS for FACS analysis. The frequencies of viable methoxy-X04 (CD11b + CD45+; microglia) were measured by flow cytometry using a CytoFlex S (Beckman) and analyzed using FlowJo (Tree Star). WT mice injected with methoxy-X04 were used as a control to determine the methoxy-X04 threshold for non-phagocytosing cells.

Intracellular Aβ clearance. Primary microglia were treated with vehicle or sTREM2 protein (160 nM) in serum-free DMEM medium for 12 h, followed by treatment with lysosomal enzyme inhibitors (Pepstatin A: 10 µM, Leupeptin: 100 µM, and E-64d: 50 µM) or chloroquine (Sigma-Aldrich, C6628, 40 µM) for 30 min and incubation with a 300 nM Aβ42 oligomer for an additional 3 h. Cells were homogenized with trypsin and cell pellets were washed twice with PBS, microglia were lysed in lysis buffer (5 M guanidine in 50 mM Tris-HCl, pH 8.0). Lysates were centrifuged at 13,400 × g at 4 °C for 15 min. Supernatants were collected and further used for quantifying the amounts of cell-associated Aβ42 using ELISA. The amounts of degraded Aβ42 were calculated by subtracting the cell-associated Aβ in the absence of inhibitors from that in the presence of inhibitors.

Electrophysiological recording. For LTP recording, experiments were performed as previously reported with modifications. In brief, animals were deeply anesthetized with isoflurane and killed by decapitation. The brain was quickly removed and dissected in an ice-cold solution containing 64 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 10 mM MgSO4, 0.5 mM CaCl2, 26 mM NaHCO3, 10 mM glucose, and 120 mM sucrose. Acute coronal slices (400 µm thickness) were cut with a vibro-slicer (VT-1000 S; Leica). Slices were allowed to recover for 30 min at 34 °C and then at RT for at least 1 h before recording in the artificial CSF (aCSF) containing 126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM CaCl2, 26 mM NaHCO3, and 10 mM glucose. Slices were transferred to the recording chamber and superfused with aCSF (2 mL/min) saturated with 95% O2/5% CO2 (volume/volume) at 34 °C. For sTREM2 protein treatment, brain slices were incubated with 50 mM recombinant sTREM2 protein for 1 h at RT, and transferred to the chamber for LTP recording. EPPSs were evoked every 20 s in the CA1 stratum radiatum by stimulating the Schaffer/commissural pathway (for CA1) with a bipolar stimulating electrode (FHC, Inc.) and recorded using a Multi-Clamp 700B amplifier (Molecular Devices) and Clampex 10.2 acquisition software (Molecular Devices) and digitized with Digidata 1550 A (Molecular Devices) with glass pipettes (1–3 MΩ) filled with aCSF. Test stimuli consisted of monophasic 0.1-mA pulses of constant current (with intensity adjusted to produce 25% of the baseline fEPSP slope) at 1 Hz. The time taken to reach the platform (escape latency) was measured, and the average of four trials was determined. If the mouse could not find the escape platform within 60 s, it was placed on the platform for 10 s. A probe trial without a platform was performed 24 h after the last trial of the hidden platform test. Percentage search time for each quadrant was recorded for 60 s. Mice were tracked by a video camera (SONY) in both training and probe trials. Collected data were analyzed by SMART 2.5 VIDEO TRACKING software (Panlab, Harvard Apparatus).

Statistical analysis. All the electrophysiological data and histologic data analyses were performed blindly. Statistical tests were performed using GraphPad Prism 5 or 6 (GraphPad Software, La Jolla, CA). Two-way ANOVA followed by Bonferroni post hoc analyses or unpaired Student’s t test was used to analyze AAAV and neuron data. Paired Student’s t test was used to analyze sTREM2 protein-injected experiments. The statistical method for each quantified data was described in the Figure legend. All data are shown as mean ± SEM and specific n values were reported in each Figure legend. Levels of significance are as follows: *p < 0.05, **p < 0.01, ***p < 0.001. p < 0.05 was considered as stastically significant.

Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The data underlying Figs. 1c, 1d, 1f, 1a, 2a, 2c, 2f, 3b, 3d, 3f, 3h, 3i, 3j, 4e, 4f, 4l, 4j, 4b, 5c, 5e, 5g, 5i, 6a, 6b, 6d, 6f, 6a, 7b, 7c, 7d, 7e, 7f, 7g, and Supplementary Figs. 1a, 2a, 2b, 3a, 3b, 3e, 3d, 3e, 4b, 4c, 4d, 4e, 4f, 4l, 4j, 4b, 5c, 5e, 5g, 5i, 6a, 6b, 6d, 6f, 6a, 7b, 7c, 7d, 7e, 7f, 7g are provided as a Source Data file. All other data that support the findings of this study are available from the corresponding author upon request.

Received: 7 September 2018 Accepted: 19 February 2019 Published online: 25 March 2019

References
1. Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405 (2015).
2. Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
3. Holtzman, D. M., Morris, J. C. & Goate, A. M. Alzheimer’s disease: the challenge of the second century. Sci. Transl. Med. 3, 77ra71 (2011).
4. Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).
5. Yoon, S. S. & Jo, S. A. Mechanisms of amyloid-beta peptide clearance: potential therapeutical targets for Alzheimer’s disease. Biomol. Ther. 20, 245–255 (2012).
6. Lee, C. Y. & Landreth, G. E. The role of microglia in amyloid clearance from the AD brain. J. Neurotransm. 117, 949–960 (2010).
7. Perlmutter, L. S., Barron, E. & Chui, H. C. Morphologic association between microglia and senile plaque amyloid in Alzheimer’s disease. Neurosci. Lett. 119, 32–36 (1990).
8. Stalder, M. et al. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 154, 1673–1684 (1999).
9. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around preexisting Tangles. Nat. Commun. 6, 6176 (2015).
10. Yuan, P. et al. TREM2 haploinsufficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid deposition and severe axonal dystrophy. Neuron 90, 724–739 (2016).

ARTICLE
12. Bertram, L. et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. *Am. J. Human Genet.* 82, 623–632 (2008).

13. Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. *New Engl. J. Med.* 368, 117–123 (2013).

14. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. *Nat. Genet.* 43, 429–435 (2011).

15. Jin, S. C. et al. Coding variants in TREM2 increase risk for Alzheimer’s disease. *Human Mol. Genet.* 23, 5388–5384 (2014).

16. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. *New Engl. J. Med.* 368, 107–116 (2013).

17. Naj, A. C. et al. Common variants at MS4A4A/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. *Nat. Genet.* 43, 436–441 (2011).

18. Sims, R. et al. Rare coding variants in PLCG2, AB3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. *Nat. Genet.* 49, 1573–1584 (2017).

19. Ethymiou, A. G. & Goate, A. M. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. *Mol. Neurodegener.* 12, 43 (2017).

20. Schmid, C. D. et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. *J. Neuroimmunol.* 83, 1309–1320 (2002).

21. Jay, T. R., von Saucken, V. E. & Landreth, G. E. TREM2 in neurodegenerative diseases. *Mol. Neurodegener.* 12, 56 (2017).

22. Wang, Y. M. et al. TREM2 lipid sensing sustains the microglial response in Alzheimer’s disease model. *Cell 160*, 1061–1071 (2015).

23. Atagi, Y. et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). *J. Biol. Chem.* 290, 26043–26050 (2015).

24. Jay, T. R., DeVaux, L. B. & Farzan, M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. *J. Biol. Chem.* 290, 26033–26042 (2015).

25. Yeh, F. L., Wang, Y., Tom, L., Gonzalez, L. C. & Sheng, M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates receptor cross-linking protein in macrophages/microglia. *Biochem. Biophys. Res. Commun.* 296, 292–297 (2001).

26. Wu, Z., Guo, Z., Gearing, M. & Chen, G. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s disease model. *Nat. Commun.* 5, 4159 (2014).

27. Tanzi, R. E. The synaptic Abeta hypothesis of Alzheimer disease. *Nat. Neurosci.* 8, 977–979 (2005).

28. Golde, T. E. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. *Brain Pathol.* 15, 84–87 (2005).

29. Weitz, T. M. & Town, T. Microglia in Alzheimer’s disease: it’s all about context. *Int. J. Alzheimer’s Dis.* 2012, 314185 (2012).

30. Heneka, M. T., Golenbock, D. T. & Latz, E. Innate immunity in Alzheimer’s disease. *Nat. Immunol.* 16, 229–236 (2015).

31. Ulrich, J. D. et al. Altered microglial response to Abeta plaques in APPPS1-2 mice heterozygous for TREM2. *Mol. Neurodegener.* 9, 20 (2014).

32. Lee, C. Y. D. et al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer’s disease models. *Neuron* 97, 1032–1048 e1035 (2018).

33. Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. *Cell 169*, 1276–1290 e1217 (2017).

34. Krassmann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* 47, 566–581 e569 (2017).

35. Parkhurst, C. N. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell 155*, 1596–1609 (2013).

36. Stellwagen, D., Beattie, E. C., Seo, J. Y. & Malenka, R. C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. *J. Neurosci.* 25, 3219–3228 (2005).

37. Viviani, B. et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium influx through activation of the Src family of kinases. *J. Neurosci.* 23, 8692–8700 (2003).

38. Kawasaki, Y., Zhang, L., Cheng, J. K. & Ji, R. R. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumour necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. *J. Neurosci.* 28, 5189–5194 (2008).

39. Liu, C. C. et al. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer’s disease. *Sci. Transl. Med.* 8, 332ra344 (2016).

40. Xu, H. et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. *Nat. Med.* 4, 457–451 (1998).

41. Heneka, M. T. et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. *Nature 493*, 674–678 (2013).

42. Wen, L. et al. VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology. *J. Cell Biol.* 195, 765–779 (2011).

43. Sun, H. & Neugebauer, V. mGluR1, but not mGluR5, activates feed-forward inhibition in the medial prefrontal cortex to impair decision making. *J. Neurophysiol.* 106, 960–973 (2011).
of Guangdong Province 2016A030306005 (to X.C.), 2016A030310371 (to R.Z.), grants from the Fundamental Research Funds for the Central Universities 20720180055 (to X.C.), grants from the Alzheimer’s Association AARG-18-56635 (to X.C.), and C4C-15-369446 (to H.X.). NIH grants R01AG056130 (to G.B. and H.X.), R01AG035355 (to G.B.), R37AG027924 (to G.B.), and R01AG056114 (to H.X.), grants from the Post-doctoral Science Foundation of China 2016M600503 and 2017T100469 (to L.Z.), a grant from the Tanz Family Funds (to H.X.), and a grant from the Natural Science Foundation of Fujian Province 2016J05203 (to R.Z.). X.C. also received funding from the Shenzhen Basic Research Program JCYT20170818140904167.

Author contributions
X.C., G.B., and Li Zhong designed the project and wrote the paper; Li Zhong and Y.X. performed all the experiments and data analyses unless otherwise indicated; T.W. and R.H. performed mouse behavioral test; Y.X. and Y.Z. purified the sTREM2 protein; R.Z., Y.G., X.S., and Lin Zhu performed the electrophysiological experiment; Li Zhong, K.W., and D.W. performed the FACS experiment; K.W., K.C., N.W., and D.C. isolated and cultured primary microglia; Li Zhong, Y.M., M.S., and C.L. set up and performed sTREM2 ELISA; H.X., L.W., H.S., and D.D. reviewed the paper. All the authors read and approved the final manuscript.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-019-09118-9.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Journal peer review information: Nature Communications thanks Li Gan, Michela Matteoli, and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019